PT  - JOURNAL ARTICLE
AU  - Kahn, Rebecca
AU  - Kennedy-Shaffer, Lee
AU  - Grad, Yonatan H.
AU  - Robins, James M.
AU  - Lipsitch, Marc
TI  - Potential biases arising from epidemic dynamics in observational seroprotection studies
AID  - 10.1101/2020.05.02.20088765
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.02.20088765
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088765.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088765.full
AB  - The extent and duration of immunity following SARS-CoV-2 infection are critical outstanding questions about the epidemiology of this novel virus, and studies are needed to evaluate the effects of serostatus on reinfection. Understanding the potential sources of bias and methods to alleviate biases in these studies is important for informing their design and analysis. Confounding by individual-level risk factors in observational studies like these is relatively well appreciated. Here, we show how geographic structure and the underlying, natural dynamics of epidemics can also induce noncausal associations. We take the approach of simulating serologic studies in the context of an uncontrolled or a controlled epidemic, under different assumptions about whether prior infection does or does not protect an individual against subsequent infection, and using various designs and analytic approaches to analyze the simulated data. We find that in studies assessing the efficacy of serostatus on future infection, comparing seropositive individuals to seronegative individuals with similar time-dependent patterns of exposure to infection, by stratifying or matching on geographic location and time of enrollment, is essential to prevent bias.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Award Number U54GM088558 from the US National Institute Of General Medical Sciences. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode will be available on github. https://github.com/rek160/serologic-studies